SpartaLabs
0
SpartaLabs Research · June 17, 2026

GHK-Cu: Discovery and Research History

A research-library account of the discovery of GHK-Cu, early copper-peptide research by Loren Pickart, and the regulatory and scientific landscape to date. Educational reference.

ghk-cucopper-peptidediscoveryresearch-historyloren-pickart

Introduction

The glycyl-L-histidyl-L-lysine–copper(II) complex (GHK-Cu) has a research history rooted in 1970s investigations of hepatocyte growth factors in human serum. Its discovery by Loren Pickart and Monroe Thaler at the University of California, San Francisco, preceded by several years the compound's recognition as a copper-binding molecule. Over the five decades since its first description in the peer-reviewed literature, GHK-Cu has moved through successive phases of characterization: chemical identification, copper-coordination studies, in vitro connective tissue biology, in vivo wound-healing models, and transcriptomic profiling. This article traces that progression based on the primary literature.

Discovery Period: 1970s

The scientific origin of GHK lies in the study of humoral factors regulating hepatocyte behavior in co-culture systems. Pickart and Thaler (1973) reported in Nature New Biology that a low-molecular-weight activity in human serum albumin fractions produced prolonged survival of normal rat hepatocytes and stimulated growth of neoplastic hepatocytes in co-culture experiments [1]. The activity was named a "growth-modulating serum factor" and its small molecular size suggested a peptide or peptide-derived structure.

Follow-up work published the same year described a synthetic tripeptide that reproduced the activity [2]. Chemical characterization of the natural serum factor and the active synthetic analogue converged on the sequence glycyl-L-histidyl-L-lysine, which was formally confirmed and reported by Schlesinger, Pickart, and Thaler in Experientia in 1977 [3]. The compound was referred to in those early years as GHL (Gly-His-Lys) and GHL-Cu interchangeably with the GHK designations now standard in the literature.

Concurrent with the sequence determination, researchers began characterizing the copper(II) coordination properties of the tripeptide. Physical chemistry studies using NMR and EPR spectroscopy, including early work by Sarkar and colleagues, established the square-planar copper coordination geometry of the GHK-Cu complex and documented its affinity for Cu²⁺ in the nanomolar range [4]. The copper-binding affinity of GHK was found to be comparable to that of the copper transport site on human serum albumin, which carries the majority of plasma copper in exchange with the portal circulation — a structural parallel that informed hypotheses about GHK's physiological role.

Early Research: 1980s

The pivotal mechanistic hypothesis from this period was articulated by Pickart and colleagues in a 1980 paper in Nature, which proposed that GHK's biological activity was mediated primarily through its capacity to facilitate copper uptake into cells [5]. This hypothesis reframed GHK-Cu not as a peptide hormone acting through receptor-mediated signaling, but as a copper shuttle that delivered bioavailable Cu²⁺ to intracellular cuproenzymes. The paper reported that maximal biological activity in hepatoma cell culture experiments was observed when the peptide was combined with both copper and iron, and that structure-activity studies pointed to the histidyl-lysyl linkage as essential for activity.

During the 1980s, the research focus shifted toward connective tissue biology. Maquart, Pickart, Laurent, Gillery, Monboisse, and Borel published the foundational in vitro collagen-synthesis study in FEBS Letters in 1988, demonstrating dose-dependent stimulation of collagen output by human fibroblast cultures exposed to GHK-Cu at femtomolar to nanomolar concentrations [6]. This paper established GHK-Cu as an object of significant interest within wound-healing biology and set the direction of the research program for subsequent decades. The wound-healing research landscape of this era also featured investigation of other connective tissue peptides, including BPC-157, whose research history similarly traces to preclinical in vitro and rodent models developed over multiple decades.

The decade's literature also included characterization of glycosaminoglycan synthesis, elastin production, and chemoattraction of repair cells, building a composite picture of GHK-Cu as a pleiotropic modulator of connective tissue matrix production. The compound was also investigated for potential utility in wound dressings and surgical collagen preparations, generating applied-research interest alongside the basic science program.

In Vivo Evidence: 1990s

The 1994 PNAS paper by Pickart and colleagues reported the most rigorous in vivo evidence available to that date, using rat subcutaneous wound chambers to quantify net connective tissue accumulation under controlled GHK-Cu exposure conditions [7]. The findings — concentration-dependent increases in collagen, glycosaminoglycan, and total protein, with a collagen-to-total-protein synthesis ratio of approximately 2:1 — have become a standard reference point for the compound's wound-healing biology and continue to be cited across the subsequent literature.

The late 1990s brought further characterization of GHK-Cu's effects on matrix metalloproteinases. Simeon and Maquart's group published in 2000 that GHK-Cu modulated both MMP-2 and TIMP-1/TIMP-2 expression in cultured fibroblasts [8], refining the understanding of GHK-Cu from a pure anabolic ECM signal to one involved in bidirectional matrix remodeling — a conceptual shift that broadened the compound's research relevance.

Regulatory Context

GHK-Cu has not been the subject of a successful new drug application (NDA) or biologics license application (BLA) with the United States FDA for any therapeutic indication. No equivalent marketing authorization for a therapeutic use has been identified in European Medicines Agency (EMA) records in the primary literature reviewed here.

The compound's presence in cosmetic formulations is governed in the United States under the cosmetics provisions of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 321(i)), which does not require pre-market approval. Cosmetic classification is a distinct regulatory category and does not constitute a therapeutic efficacy determination.

GHK-Cu appears in the INCI (International Nomenclature of Cosmetic Ingredients) dictionary as "copper tripeptide-1," reflecting its cosmetics-industry use. No clinical trial registration records for human interventional trials of GHK-Cu as a drug or therapeutic have been identified in the primary peer-reviewed literature within the scope of this review. Synthesis standards and third-party verification practices for research-grade material are described in the GHK-Cu sourcing and quality article.

Current Research Landscape

From approximately 2010 onward, GHK-Cu research has been substantially expanded by the availability of large-scale gene-expression profiling tools, particularly the Broad Institute Connectivity Map (CMap). Pickart, Vasquez-Soltero, and Margolina published a series of papers using CMap data to characterize GHK's transcriptional footprint, with analyses focused on antioxidant gene networks (2015), nervous system gene expression (2017), and broad regenerative gene-expression patterns (2018) [9, 10, 11]. These analyses extended the scientific discussion of GHK-Cu into new biological domains and generated pharmacogenomic hypotheses that have attracted independent follow-on research.

An independent line of research has emerged from pulmonary biology. Two published rodent studies — one on bleomycin-induced pulmonary fibrosis (Zhou et al., 2017) [12] and one on cigarette-smoke-induced emphysema (Zhang et al., 2022) [13] — represent research groups outside Pickart's laboratory working with GHK-Cu in disease models. This diversification of the research base introduces independent experimental perspectives into a literature that had previously been centered heavily on a single research program.

The most recent substantive addition to the published record identified in this review is a 2024 paper by He, Mazzola, and Ladiges at the University of Washington, which reviewed GHK's potential effects on myofibroblast function and age-related fibrosis [14]. The authors drew on available literature to propose mechanistic models involving integrin-β1 signaling and cellular senescence pathways, and situated GHK within the broader framework of geroscience research — representing a continued expansion of the compound's research scope.

The overall state of the research landscape as of the literature reviewed here is one of sustained and broadening preclinical activity. The compound has an extensive published history in in vitro and rodent models, a growing body of transcriptomic analysis, and an emerging presence in the geroscience literature. Independent replication of core findings by groups outside the original Pickart research program has increased notably over the most recent decade. Researchers interested in sourcing GHK-Cu for laboratory investigation can review batch-specific purity data and certificates of analysis for GHK-Cu from SpartaLabs on the product page.

References

  1. Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973;243(124):85–87. PMID: 4349963. https://pubmed.ncbi.nlm.nih.gov/4349963/

  2. Pickart L, Thaler MM. A synthetic tripeptide which increases survival of normal liver cells, and stimulates growth in hepatoma cells. Nat New Biol. 1973;243(124):85–87. [PMID: 4356974 for the synthetic compound characterization.] https://pubmed.ncbi.nlm.nih.gov/4356974/

  3. Schlesinger DH, Pickart L, Thaler MM. Growth-modulating serum tripeptide is glycyl-histidyl-lysine. Experientia. 1977;33(3):324–325. PMID: 858356. https://pubmed.ncbi.nlm.nih.gov/858356/

  4. Laussac JP, Sarkar B. Characterization of the copper(II)- and nickel(II)-transport site of human serum albumin. Studies of copper(II) and nickel(II) binding to peptide 1-24 of human serum albumin by ¹³C and ¹H NMR spectroscopy. Biochemistry. 1984;23(12):2832–2838. [See also the copper coordination studies in: PMC1163421 and PMC1154122.]

  5. Pickart L, Freedman JH, Loker WJ, Peisach J, Perkins CM, Stenkamp RE, Weinstein B. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 1980;288(5792):715–717. PMID: 7453802. https://pubmed.ncbi.nlm.nih.gov/7453802/

  6. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343–346. PMID: 3169264. https://pubmed.ncbi.nlm.nih.gov/3169264/

  7. Pickart L, Freedman JH, Loker WJ, Peisach J, Perkins CM, Stenkamp RE, Weinstein B. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. Proc Natl Acad Sci USA. 1994;91(24):11069–11073. PMC: PMC288419. https://pmc.ncbi.nlm.nih.gov/articles/PMC288419/

  8. Simeon A, Wegrowski Y, Bontemps Y, Maquart FX. Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. J Invest Dermatol. 2000;115(6):962–968. PMID: 11045606. https://pubmed.ncbi.nlm.nih.gov/11045606/

  9. Pickart L, Vasquez-Soltero JM, Margolina A. GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes. Cosmetics. 2015;2(3):236–247. DOI: 10.3390/cosmetics2030236. https://doi.org/10.3390/cosmetics2030236

  10. Pickart L, Vasquez-Soltero JM, Margolina A. The effect of the human peptide GHK on gene expression relevant to nervous system function and cognitive decline. Brain Sci. 2017;7(2):20. PMC: PMC5332963. https://pmc.ncbi.nlm.nih.gov/articles/PMC5332963/

  11. Pickart L, Vasquez-Soltero JM, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PMC: PMC6073405. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/

  12. Zhou XM, Wang GL, Wang XB, Liu L, Zhang Q, Yin Y, Wang QY, Kang J, Hou G. GHK peptide inhibits bleomycin-induced pulmonary fibrosis in mice by suppressing TGFβ1/Smad-mediated epithelial-to-mesenchymal transition. Front Pharmacol. 2017;8:904. PMC: PMC5733019. https://pmc.ncbi.nlm.nih.gov/articles/PMC5733019/

  13. Zhang Q, Yan L, Lu J, Zhou X. Glycyl-L-histidyl-L-lysine-Cu2+ attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway. Front Mol Biosci. 2022;9:925700. PMID: 35936787. PMC: PMC9354777. https://pmc.ncbi.nlm.nih.gov/articles/PMC9354777/

  14. He Q, Mazzola J, Ladiges W. The naturally occurring peptide GHK reverses age-related fibrosis by modulating myofibroblast function. [Peer-reviewed journal, University of Washington.] 2024. PMC: PMC12352503. https://pmc.ncbi.nlm.nih.gov/articles/PMC12352503/

Frequently asked questions

  • When was GHK-Cu discovered?

    GHK was first isolated from human albumin and reported in Nature New Biology in 1973 by Loren Pickart and Monroe Thaler at the University of California, San Francisco. The full amino acid sequence glycyl-L-histidyl-L-lysine was formally confirmed and published by Schlesinger, Pickart, and Thaler in Experientia in 1977.

  • Who discovered GHK-Cu?

    GHK was discovered by Loren Pickart and Monroe Thaler during research on hepatocyte growth factors at the University of California, San Francisco. Pickart subsequently led the research program that characterized the compound's copper-binding properties and connective tissue biology over several decades.

  • What is the regulatory history of GHK-Cu?

    GHK-Cu has not been the subject of a successful new drug application or biologics license application with the United States FDA for any therapeutic indication. The compound's presence in cosmetic formulations is governed under the cosmetics provisions of the Federal Food, Drug, and Cosmetic Act, which is a distinct regulatory category from drug approval. No clinical trial registration records for human interventional trials of GHK-Cu as a drug or therapeutic have been identified in the primary peer-reviewed literature reviewed here.

  • What was the significance of the 1980 Nature paper on GHK-Cu?

    The 1980 paper in Nature by Pickart and colleagues proposed the pivotal mechanistic hypothesis that GHK's biological activity was mediated primarily through its capacity to facilitate copper uptake into cells. This framed GHK-Cu not as a peptide hormone acting through receptor-mediated signaling, but as a copper shuttle delivering bioavailable Cu²⁺ to intracellular cuproenzymes — a hypothesis that has remained the most mechanistically grounded explanation in the subsequent literature.

  • What research developments occurred for GHK-Cu from the 2010s onward?

    From approximately 2010 onward, GHK-Cu research expanded substantially through the use of large-scale gene-expression profiling tools, particularly the Broad Institute Connectivity Map. Pickart, Vasquez-Soltero, and Margolina published a series of analyses characterizing GHK's transcriptional footprint in antioxidant gene networks, nervous system gene expression, and broad regenerative gene-expression patterns. Independent research groups also examined GHK-Cu in pulmonary fibrosis and emphysema animal models during this period.